Van Andel Research Institute, Grand Rapids, MI 49503, USA.
Proteomics. 2011 Sep;11(18):3665-74. doi: 10.1002/pmic.201000827. Epub 2011 Aug 2.
The current best serum marker for pancreatic cancer, CA 19-9, detects a carbohydrate antigen on multiple protein carriers. Better knowledge of the protein carriers of the CA 19-9 antigen in various disease states may lead to improved diagnostic tests. To identify proteins that carry the CA 19-9 antigen, we immunoprecipitated the CA 19-9 antigen from pooled sera and identified the associated proteins using MS. Among the high-confidence identifications, we confirmed the presence of the CA 19-9 antigen on Apolipoprotein B-100 by antibody arrays and Western blot and on kininogen, ARVCF, and Apolipoprotein E by antibody arrays. We characterized the frequency and levels of the CA 19-9 antigen on the four proteins across various patient groups (pancreatic cancer, pancreatitis, and healthy controls) using antibody arrays. Nearly, 10-25% of the subjects showed elevations of the antigen on each protein, but the elevations were not associated with disease state or total CA 19-9 levels. These results contribute to our knowledge of the carrier proteins of an important functional glycan and the rate at which the glycan is displayed. This work also demonstrates a strategy for using the complementary methods of MS and antibody microarrays to identify protein carriers of glycans and assess the diagnostic value of measuring glycans on individual proteins.
当前用于胰腺癌的最佳血清标志物 CA 19-9 可检测到多种蛋白质载体上的碳水化合物抗原。更好地了解不同疾病状态下 CA 19-9 抗原的蛋白质载体可能会导致改进的诊断测试。为了鉴定携带 CA 19-9 抗原的蛋白质,我们从混合血清中免疫沉淀 CA 19-9 抗原,并使用 MS 鉴定相关蛋白质。在高可信度的鉴定中,我们通过抗体阵列和 Western blot 证实了 CA 19-9 抗原存在于载脂蛋白 B-100 上,并通过抗体阵列证实了激肽原、ARVCF 和载脂蛋白 E 上存在 CA 19-9 抗原。我们使用抗体阵列在各种患者群体(胰腺癌、胰腺炎和健康对照者)中对四种蛋白质上的 CA 19-9 抗原的频率和水平进行了特征描述。将近 10-25%的研究对象在每种蛋白质上均显示抗原升高,但这些升高与疾病状态或总 CA 19-9 水平无关。这些结果有助于我们了解重要功能糖的载体蛋白以及糖展示的速度。这项工作还展示了一种使用 MS 和抗体微阵列互补方法来鉴定糖蛋白载体并评估测量单个蛋白质上糖的诊断价值的策略。